S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up

• Published in: Journal der Deutschen Dermatologischen Gesellschaft Vol. 17; no. 2; pp. 214 - 230
• Main Authors: Lang, Berenice M., Balermpas, Panagiotis, Bauer, Andrea, Blum, Andreas, Brölsch, G. Felix, Dirschka, Thomas, Follmann, Markus, Frank, Jorge, Frerich, Bernhard, Fritz, Klaus, Hauschild, Axel, Heindl, Ludwig M., Howaldt, Hans‐Peter, Ihrler, Stephan, Kakkassery, Vinodh, Klumpp, Bernhard, Krause‐Bergmann, Albrecht, Löser, Christoph, Meissner, Markus, Sachse, Michael M., Schlaak, Max, Schön, Michael P., Tischendorf, Lutz, Tronnier, Michael, Vordermark, Dirk, Welzel, Julia, Weichenthal, Michael, Wiegand, Susanne, Kaufmann, Roland, Grabbe, Stephan
• Format: Journal Article
• Language: English
• Published: Germany Wiley Subscription Services, Inc 01-02-2019
• Subjects: Aged; Aged, 80 and over; Basal cell carcinoma; Carcinoma, Basal Cell - epidemiology; Carcinoma, Basal Cell - pathology; Carcinoma, Basal Cell - prevention & control; Carcinoma, Basal Cell - therapy; Disease Management; Follow-Up Studies; Germany - epidemiology; Humans; Incidence; Managed Care Programs - standards; Middle Aged; Neoplasm Recurrence, Local - epidemiology; Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - prevention & control; Patients; Practice Guidelines as Topic; Quality of Health Care - standards; Risk Assessment; Skin; Skin cancer; Skin Neoplasms - epidemiology; Skin Neoplasms - pathology; Skin Neoplasms - therapy; Germany
• ISSN: 1610-0379; 1610-0387
• DOI: 10.1111/ddg.13755

SummaryBasal cell carcinoma (BCC) is the most common malignant tumor among fair‐skinned individuals, and its incidence had been steadily rising in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 2 addresses issues such as proper risk stratification, the various therapeutic approaches, and prevention as well as follow‐up of patients with basal cell carcinoma.